November 11-12, 2021 

Online Streaming 

Lifescience and pharma professionals are invited to attend the 2nd Rx to OTC symposium being held on November 11-12, 2021. The online event is hosted by Dynamic Global Events (“DGE”), a global event company that caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. 

Become a part of this 2-day communication and networking symposium to understand the complexities, implications, and benefits of switching a product from prescription to over the counter. In keeping with the need of the hour that involves the consumer taking pivotal decisions about their health, the increasing availability of over the counter medicines relieves the burden of cost and improves accessibility. The successful RX to OTC Switch requires strategic planning and preparation where consumers can self-diagnose, self-treat and self-manage on their own. Also, the drug must have low potential for misuse and abuse.  

Switching a medicine from prescription to over the counter requires the help of a cross functional team including regulatory, clinical, and marketing.  

DGE’s Rx to OTC Switch Symposium provides an excellent platform to bring together industry leaders and specialists who will discuss the latest challenges and opportunities in switches including  

• regulatory and data requirements that may be needed depending on the nature of the switch 
• digital tools to enable switching in more difficult categories 
• the impact of increasing use of telemedicine on the potential for a switch 

The topics covered at the symposium: 

• Gain a summary of lessons learned from recent successful switches 
• Examine the global landscape for switches 
• Use digital technology to accompany more complex products 
• The impact of telemedicine on health care coordination  
• Identify the areas most currently active for switch candidates 
• Understand the latest trends on DTC companies causing a barrier to traditional   switch and the current consumer landscape 
• Scrutinize strategies for commercializing switches and retail execution 
• Identifying the road ahead from the FDA and regulatory approaches 
• Learn about the latest digital trends 
• Determine how to manage COVID related regulatory and clinical delays

For additional information, visit https://ibn.fm/otV6s



• Mineral property exploration company StraightUp announced Sept. 28 that it is expanding its footprint with the acquisition of a mine in Nevada’s historic Bullfrog boom zone about 125 miles northwest of Las Vegas
• The company recently completed high-resolution heli-borne magnetic surveys (“MAG”) on its largest properties in Ontario, and on another nearby property in a renowned greenstone belt
• Both regions have generated excitement among explorers as gold prices have climbed sharply during the past four years, with analysts predicting the potential for continued increases if market instability resumes during the ongoing COVID pandemic
• The Nevada mine is in an area that produced about 2.3 million ounces of gold and more than 3 million ounces of silver during the 1990s

Canada-based mineral exploration and mining property acquisition company StraightUp Resources (CSE: ST) is adding a historically productive mine within the renowned Bullfrog   boom zone of southwestern Nevada to its Ontario greenstone belt options as new interest in gold production begins to manifest itself across North America. StraightUp announced the acquisition of the West Cat Mine, which includes an unpatented lode mining claim on a 20.66-acre package in federal land, Sept. 28 in a news release that expressed the company’s excitement to be expanding into new mining districts while continuing to evaluate the potential of multiple options in the heart of Ontario’s Red Lake Mining District. “This is clearly an area ready for large-scale operations to come,” StraightUp President and CEO Mark Brezer stated (https://nnw.fm/fWJfS). (https://ibn.fm/SXZ3x). “(Nevada is) the second-largest (silver) producer in the United States, after Alaska, and, in 2014, Nevada produced roughly 11 million troy ounces — more than half of which came as a byproduct from gold mining.” StraightUp’s announcement came the same day as news that gold prices had retreated to $1,722.50 per ounce near the year’s Aug. 10 lows (https://ibn.fm/RmMi4). But overall gold prices have been vigorously marking new territory since September 2018 when they were at $1,202.44, notably driven by the COVID-19 pandemic (https://ibn.fm/t4TMq), and analysts continue to anticipate gold prices could resume their climb this fall if the U.S. dollar’s recent rally loses steam during the historically turbulent month of October. Barrick Bullfrog Inc. produced about 2.3 million ounces of gold and more than 3 million ounces of silver during the 1990s from its property in the Bullfrog boom zone near Beatty, Nev., shuttering the project when prices fell (https://ibn.fm/JFyvI). The area has generated new excitement among explorers in recent months, as demonstrated by South Africa-based gold miner AngloGold Ashanti’s definitive agreement for about US$370 million to acquire its remaining stake in Canadian firm Corvus Gold, which owns the North Bullfrog and Mother Lode projects as well as other exploration assets in Nevada (https://ibn.fm/6xFvo). The Beatty Mining District is located near U.S. Highway 95, about 125 miles northwest of Las Vegas’ metropolitan transportation hub. According to StraightUp, the West Cat Mine has reportedly produced some very rich gold ore from quartz veins high in base metals within fault zones and shears that also cut dolomite limestones and metamorphic schists. StraightUp will pay the cash equivalent of CA$50,000 and issue 4 million common shares at a deemed price of CA$0.25 per share to complete the deal. In Ontario, the company has recently completed high-resolution heli-borne magnetic surveys (“MAG”) on its 10,000-hectare (about 25,000-acre) RLX North and RLX South properties, and on its 6,600-hectare (16,308-acre) Ferdinand Gold Project, where ground work exploration has since begun (https://ibn.fm/1dq4R). A company specializing in structural interpretation will begin processing the Ferdinand data in October with the final report from the RLX survey also due. StraightUp has also optioned the 2,000-hectare (4,942-acre) Belanger property and the 1,944-hectare (4,803-acre) Bear Head Gold Project in the district known for producing over 30 million ounces of gold historically. A nearby GoldON Resources project announced Sept. 29 that initial mapping and sampling on its property located five new gold showings in a variety of environments not historically recorded within the entire greenstone belt (https://ibn.fm/Kgd9D) as a demonstration of the region’s ongoing potential. StraightUp has undertaken a non-brokered financing to raise up to CA$2 million to continue advancing its projects. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to ST are available in the company’s newsroom at https://ibn.fm/STR

• Panama’s National Assembly recently passed a bill legalizing cannabis for medical use
• Plans are already in place to establish a technical council on cannabis, a national register of qualified users, and the issuance of seven licenses for import and domestic production of cannabis-based medicinal products
• Robust Farms Inc., a Panama-based importer and distributor, is set to receive its cannabis import license
• Flora has entered into a non-binding LOI with Robust to initially supply its premium CBD-derivative products from its Kasa Wholefoods division
• This marks a significant move in Flora’s overall global expansion plan

Years of research have shown that medical cannabis is helpful for pain control. It has also proven effective as a muscle relaxant, and it has even been shown to lessen tremors in Parkinson’s disease. Other ailments it has been known to manage include endometriosis, fibromyalgia, interstitial cystitis, and other conditions where the final common pathway is chronic pain (https://ibn.fm/vubpZ). Governments worldwide are slowly warming up to the idea of legalizing cannabis for medical use, having weighed the pros and cons of such a move. In the United States, 18 states, and Washington, DC, have legalized the product, and over 30 countries around the world have done so as well (https://ibn.fm/R3BWs). The latest addition to that list is Panama. Having passed a bill in the National Assembly on August 30, 2021, it is now awaiting the president’s signature to be approved into law (https://ibn.fm/IAUDg). In the meantime, systems are already in place to establish a technical council on cannabis, a national register of qualified users, and the issuance of seven licenses for import and domestic production of cannabis-based medicinal products (https://ibn.fm/qU1s9). One of the licenses is set to be issued to Robust Farms Inc. Flora Growth (NASDAQ: FLGC) has, since its inception, remained focused on global growth, as evidenced by its strategic global distribution platform, along with an expansive brand and product portfolio. With the legalization of cannabis for medical use in Panama, Flora recognizes the opportunity therein and has already entered into a non-binding Letter of Intent (“LOI”) with Robust to supply its premium cannabidiol (“CBD”)-derivative products from its Kasa Wholefoods division (https://ibn.fm/GcEti). This move will see Panama added to the list of Flora user markets, including Australia, different countries in Latin America, Europe, and Asia (https://ibn.fm/Lfv0r). Additionally, it will position Flora strategically in the Central American market, mainly since Panama is the first country in that region to open a regulated market. “We’re extremely pleased to enter into this agreement with Flora in order to pre-emptively secure access to their medical-grade cannabis products- which we believe is the first of its kind to be announced since the cannabis legislation passed- and look forward to supplying our clients with Flora’s premium portfolio of CBD-infused and non-CBD food and beverage products in the short term,” noted Maurice Holmes Mendez, the Chief Executive Officer (“CEO”) of Robust (https://ibn.fm/aZzEZ). Already, Robust is doing all the requisite groundwork, building its medical cannabis sales channels in the Latin America (“LATAM”) region in readiness for its partnership with Flora. This LOI marks a significant move for Flora as it sets its eyes on expanding even further to other regions and markets worldwide. It follows the recent €2 million investment in Hoshi international Inc. as part of its European expansion plan (https://ibn.fm/KTDE1). Given what the company has achieved so far, it is easy to see why its future looks promising. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

Date: November 4-5, 2021 Online Streaming Lifescience and healthcare professionals across all department functions, and consultants are invited to attend DGE’s Advancing Diversity, Equity & Inclusion (“DEI”) In Pharma & Healthcare Conference, streaming live online November 4-5, 2021. The event is hosted by Dynamic Global Events (“DGE”), a global Life Science leader in organizing b2b events. The company supports the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. Igniting change and implementing new initiatives to create a more diverse and inclusive culture is paramount for the success of the life science and healthcare industries.  An inclusive organization positively impacts drug development and is a key enabler to improving diversity in clinical trials. The live streaming event serves as a networking arena to connect with prominent industry leaders at the forefront of their professions who are making a real difference in advancing their organization’s DEI initiatives. The event features thought leaders from pharmaceutical, biotechnology and medical device organizations of all sizes who will share innovative and successful strategies essential to addressing and advancing diversity and inclusion across all functions of the organization, and key insights to ensure a more diverse patient population in clinical trials The event highlights the need for medical affairs and clinical trial leaders to collaborate and strengthen their relationships with external stakeholders and gain a greater understanding of the challenges impacting diversity and inclusion in clinical trials. The robust agenda will provide attendees with a blueprint to strategically eliminate environmental barriers to diversity and inclusion and set their organization on a path to building and sustaining a culture of belonging—achieve and sustain DEI success. Themes include:

• Diversity In Clinical Trials & Drug Development Recruitment
• Retention & Workforce Management
• Emphasizing Equality And Inclusion In The Workplace
• Leadership & Career Development
• Measuring Current And Future DEI Progress

Session Highlights:

• Integrate D&I Into Talent Recruitment and Acquisition To Transform Your Workforce and
• Culture
• Rebuild DEI Strategy from a Functional Perspective
• Increase Diversity Among Leadership and Boards
• Develop Managers To Drive Engagement in DEI Initiatives
• Partner With External Stakeholders to Build Trust and Improve Clinical Trial Diversity

The Advancing Diversity, Equity and Inclusion in Pharma and Healthcare event will help you become a confident leader in this crucial business space – more important than ever and growing every year. Join us for 2-days of learning and networking to uncover how industry leaders across the life science and healthcare industries are building a culture of inclusivity and engagement. To learn more about the virtual event, please visit https://ibn.fm/V1E4b.

• Red White & Bloom Brands Inc. is a multi-state operator building steam within the cannabis market, particularly with recent growth developments in Florida and Michigan
• The company has obtained prequalification status for recreational use marijuana production in Michigan, and built out a production facility in Florida for edibles and other cannabis derivatives
• Florida is the nation’s third-largest market for cannabis and the largest for medical cannabis
• Red White & Bloom has named former congressman and current policy strategist Ryan Costello to its board to help drive the company’s plans for expansion

Cannabis multi-state operator and brand builder Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is positioning itself to become a market leader in the U.S. legal cannabis and hemp sector, announcing recently that it has welcomed former U.S. Congressman and now-public policy consultant Ryan Costello to its Board of Directors (https://ibn.fm/JV7YB). Costello, an experienced strategist who advises companies on matters before legislative and administrative agencies, has a wealth of knowledge on healthcare, energy, environmental, technology and transportation matters. He will “deepen the Company’s U.S.-based representation, which is key, as federal policy on cannabis shifts through many of the bills scheduled to reach the House of Representatives and Senate over the near future,” Chairman and CEO Brad Rogers stated in the news release. As an example of Red White & Bloom’s growing strength in its pursuit of stature as one of the top three multi-state cannabis operators active in the United States, the company announced earlier this month that it has built-out a new production facility to good manufacturing practice (“GMP”) specifications in Florida as part of an effort to capitalize on the growing cannabis derivative market there (https://ibn.fm/AY6Ru). Florida has become a battleground for U.S. multi-state operators, having established itself as the third-largest cannabis market in the country by annual sales and the largest market for medical marijuana, according to a recent Forbes report (https://ibn.fm/6QULM). “When we think about the future catalyst ahead in Florida, and we think about it going recreational and having the ability to sell to 130 million tourists every year, the opportunity is significant,” one company’s CEO told Forbes. “I don’t believe that there’s another market like it currently in the U.S.” The legalization of adult recreational use cannabis appears to be a few years away yet given the state Supreme Court’s response to the most recent legislative efforts, but advocates believe the momentum is building at a solid pace. Red White & Bloom has built a branded capsule and rosin line as well as a proprietary line of chocolates that the company expects to have out to medical patients by the end of the year. The Florida facility is a 4,800-square-foot standalone structure built to accommodate demand for edibles that grew from $5.3 million a month to over $13 million a month during the first half of the year, according to data provided by analysts at cannabis market watcher BDSA (https://ibn.fm/BNPf1). Elsewhere, Red White & Bloom received adult recreational use prequalification status in Michigan earlier this month as it works through the licensing provisions and associated rules in that state. “This now provides a clear path for us to fully execute on our strategy of being the house of brands and being great channel partners to all of our distribution points as well as our own planned flagship retail locations,” Rogers stated in the announcement (https://ibn.fm/iCUZ1). For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures
• Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits
• Better communication between patients and their healthcare providers impacts adherence to prescribed treatment

According to a report published in Dove Medical Press, communication between patients and their physicians has a notable impact on adherence to prescribed treatment and improved health care (https://ibn.fm/ZMYMQ). As a company focused on providing digital and glucose monitoring solutions for patients dealing with diabetes, Nemaura Medical (NASDAQ: NMRD) pays special attention to essential information and research that impacts the successful implementation of its solutions. “Many patients are not satisfied with how their doctors communicate with them,” the report states. “Patients want to be more involved in planning their care and making decisions about their treatment. It is often difficult for patients to understand all the instructions from their doctors, especially when they receive too much information at one time. This is especially true for patients with chronic diseases, such as diabetes, where treatment is complicated and lifelong. Using electronic methods, such as smartphones, email, or text message, may help improve communication between patients and doctors.” These conclusions originate from a study titled “Mechanisms for improving diabetes patient–provider communication through optimal use of e-clinical technologies.” The study included a survey of 105 participants with type 2 diabetes, which indicated that most participants were interested in using electronic methods to communicate more with their doctors between visits. “Participants showed interest in using email to communicate with their doctor, and using a smartphone for medication reminders and scheduling doctor visits,” the report noted. “Patients need support and encouragement from their doctors, especially when dealing with lifelong complicated treatments, such as for type 2 diabetes. Our study shows that patients with type 2 diabetes are willing and interested in using electronic methods to increase communication with their doctors to manage their disease. This suggests that health care providers should consider using electronic methods to increase communication with the goal to improve health care.” These findings are particularly interesting to Nemaura, which has developed a proprietary technology that replaces traditional invasive methods of glucose monitoring that can be useful in disease management and diagnosis. NMRD’s BEAT(R) solution allows for continuous remote monitoring of chronic diseases and health conditions. Based on a world-class program initially developed at the Joslin Diabetes Center, BEAT is designed to help people with diabetes manage their condition and even potentially reverse type 2 diabetes using a combination of data from a wearable sensor and digital intervention and coaching. Nemaura’s BEAT is combined with the company’s proprietary sugarBEAT(R) sensor platform, which is the world’s first non-invasive daily-wear continuous glucose monitoring designed for use by people with both type 1 and type 2 diabetes as well as pre-diabetes, to trend glucose profiles. “Importantly, as a daily disposable adhesive skin-patch that sits on the surface of the skin, SugarBEAT is painless and versatile in terms of wear time,” said Nemaura CEO Dr. Faz Chowdhury (https://ibn.fm/GQZuV). “Due to the non-invasive nature of the sensor patch and connection to a rechargeable transmitter, SugarBEAT will allow users the freedom to decide when, and for how long to wear the patch.” This commitment to offering solutions designed to support patients in their treatment plans makes Nemaura distinctive — and that makes reports like the one published by Dove exciting. The company recently tweeted about the report (https://ibn.fm/qioHz), noting “the power of patient–provider communication. Optimal use of e-clinical technologies paves the way.” For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• “CBD may offer an option for treating different types of chronic pain,” reports Harvard article
• Topical CBD could help lower pain and inflammation due to arthritis, notes one study
• According to Simply Sonoma, the inflammation market represents a $100-billion opportunity and is one of three areas the company is working in

CBD, or cannabidiol, the second most prevalent of the active ingredients of cannabis, is gaining attention as a potential effective therapy for many uses, including inflammation. A recent article from Harvard Health Publishing notes the progress being made in that area (https://ibn.fm/xlwDr), an area that Simply Sonoma is heavily focused on. “CBD stands for cannabidiol,” the article stated. “It is the second most prevalent of the active ingredients of cannabis (marijuana). While CBD is an essential component of medical marijuana, it is derived directly from the hemp plant, which is a cousin of the marijuana plant. While CBD is a component of marijuana (one of hundreds), by itself it does not cause a ‘high.’ According to a report from the World Health Organization, ‘In humans, CBD exhibits no effects indicative of any abuse or dependence potential. . . . To date, there is no evidence of public health-related problems associated with the use of pure CBD.’ “CBD may offer an option for addressing different types of chronic pain. A study from the ‘European Journal of Pain’ showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis,” the article continued. “Another study demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat. More study in humans is needed in this area to substantiate the claims of CBD proponents about pain control.” According to Allied Market Research, the global pain management and inflammation market is expected to reach nearly $92 million dollars by 2027 and is one of three areas the company is working in; the other two are sleep aids, a $71-billion market, and the gut and probiotic health market, $54.77 billion in 2020. Simply Sonoma’s product development consists of clean, organic ingredients combined with a solar-first approach, resulting in as close to zero C02 emissions as possible. The company is currently working on an array of new products, including a joint/pain cream, as well as a nonalcoholic beverage made from grapes grown in Sonoma County. Simply Sonoma, a CBD company focused on building a reputation as a leader in plant-based medicinal health and beauty products. Specifically, Sonoma is developing broad-spectrum CBD products for therapeutic applications from a scientific perspective. Its products come from the farm rather than from a lab, with the goal of achieving fewer side effects and more efficacy for patients. The company is committed to incorporating published, science-based trials and research into the formulation and manufacture of its CBD offerings. “At Simply Sonoma, we strive to create the best organically grown medicinal products,” the company states. “We’re creating unique medicinal hemp strains that are alternatives and supplements to traditional, chemically manufactured therapies. We believe in all-natural, organically sun-grown, plant-based medicinals. We provide consumers with science-based education on CBD for disease and lifestyle needs. In our commitment to minimize our carbon footprint, we are powering our operations off the grid with solar.” Simply Sonoma is a different kind of natural company and looks forward to introducing its exceptional products to the consumer market. For more information, or to invest in Simply Sonoma, visit the company’s website at www.SimplySonoma.org. NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• RYAH Group is a digital healthcare analytics and technology company focused on developing tools that provide patients and doctors with the ability to accurately manage the intake in plant-based treatment
• The company recently revealed its participation at the Wall Street Reporter’s ‘Next Super Stock’ livestream conference held on September 23, 2021

RYAH Group (CSE: RYAH) is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. The company specializes in developing volume-control IoT devices to provide accurate volume control and management for various medical purposes. RYAH Group’s management recently revealed their attendance at the Wall Street Reporter’s “Next Super Stock” livestream conference, held on September 23, 2021  (https://ibn.fm/QtOfB). Wall Street Reporter’s Next Super Stock conference (https://ibn.fm/f5977) features select companies with major near-term catalysts in place to drive transformational growth (and stock appreciation) in the months ahead. Due to the ‘Next Super Stock’ conference’s track record showcasing companies which have enjoyed exponential increases in the weeks following the conference, hundreds of institutional investors habitually attend the meeting in anticipation of discovering the next big breakthrough. RYAH Group’s current product portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component, and the mobile application. The product line currently includes a Smart Dry-Herb Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage, and a Smart Liquid Dispensing Pen in the prototype stage. The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and pre-sets for temperatures and volumes. All of these features are customizable to individual needs and doctor recommendations. The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and heating element are completely IoT and controlled by RYAH’s proprietary smartphone applications, allowing on-demand scheduling and ‘boosting’ medicine release. RYAH’s Smart Liquid Dispensing Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect,’ enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. RYAH Group’s product suite of precision intake and volume management devices provides patients and medical practitioners with a practical toolkit to abide by volume control guidelines safely and accurately. In addition, detailed analytics provided by these RYAH devices help determine which intake volumes are working and what needs adjusting, along with accurately depicting a patient’s progress in their treatment. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• SRAX’s subsidiary BIGtoken to enter merger with Britepool, company providing identity resolution and verification services for advertisers and publishers
• SRAX expects transaction to benefit company’s shareholders with exchange of its shares for preferred shares with blockers at 4.99% and or 9.99%
• Combined entity boasts highly experienced management team, appears poised to provide next-gen privacy-focused solutions

SRAX (NASDAQ: SRAX), a financial technology company focused on improving communications between public companies and their investors, has recently announced the merger between its subsidiary Force Protection Video Equipment Corp. (“FPVD”), also known as BIGtoken, and Britepool, an identity resolution and verification service for advertisers and publishers (https://ibn.fm/g0QqH). As part of the transaction, SRAX is expected to exchange its approximately 150 billion shares for preferred shares with blockers at 4.99% and or 9.99%. This move will allow the company to recognize the value of the asset on its balance sheet without the need to consolidate BIGtoken’s operating results. It will also allow company’s investors to recognize the true operating performance of the Sequire, its software-as-a-service platform that unlocks data and insights for publicly traded companies. SRAX expects the transaction, which is awaiting regulatory approval, to benefit the company’s shareholders. “The movement of our position to a preferred share, which is currently worth a significant amount of money, will be very beneficial for our shareholders. The market will now be able to understand the true value that SRAX is generating on its own. We are currently exploring the best way to maximize the value of this asset for our shareholders,” said Christopher Miglino, Founder and CEO of SRAX. The merger is anticipated to close in approximately thirty days. The company is positive that the combined entity boasts strong leadership. “We are excited for the BIGtoken and BritePool teams to come together for this merger. The new combined management team is incredible,” added Miglino. The new company’s CEO will be David Moore, a digital advertising pioneer who was previously a partner in BritePool. George Stella, a veteran ad tech executive and a co-founder and president of BIGtoken, will continue to serve as the president after the merger (https://ibn.fm/DwCLE). As a company offering identity resolution and verification services for advertisers and publishers, BritePool provides precise, frequency-controlled identity targeting without third-party cookies. BIGtoken serves as a data marketplace that encourages users to share information in exchange for incentives. The combined entity will aim to provide the next evolution of privacy-focused solutions, with benefits for consumers and advertisers. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share
• Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
• Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology
• DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery across the blood-brain barrier
• The relatively low-cost technology has the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships

Oral drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) has drawn the attention of Zacks Small-Cap Research analysts, who have initiated coverage of Lexaria with a valuation of $15 per share because of the company’s patent portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption technology and the multiple potential uses of the technology. DehydraTECH pairs active pharmaceutical ingredients (“APIs”) with select long-chain fatty acid (“LCFAs”) oils that serve as carriers for the APIs though the lymphatic system, converting these compounds into ingestible formats that can be readily administered in capsules or liquid mixtures. Zacks focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators (https://ibn.fm/9XRDS). “Interest in using (DehydraTECH) extends across many categories beyond the primary pharmaceutical focus of the company from foods to beauty products and nutraceuticals, and across a range of formats from oral ingestible to oral buccal/sublingual to topical products,” Zacks notes in a news release issued Sept. 23 (https://ibn.fm/3FTTE). But thus far, Lexaria’s testing has focused on potential uses of DehydraTECH in treating high blood pressure (hypertension) in combination with cannabidiol (“CBD”), as well as in battling viruses through combination with such antivirals as remdesivir and colchicine and in providing alternatives to tobacco smoking through nicotine replacement therapy oral pouches. Clinical and preclinical studies have advanced Lexaria’s API toward commercialization in these areas, but DehydraTECH is already being used in CBD-based nutraceutical products distributed through retailers such as Albertson’s, Safeway and Hudson News stores. Zacks notes the potential market reach of Lexaria’s technology if regulatory-approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances. Lexaria’s use of the lymphatic system for bioavailability allows APIs to achieve more rapid delivery to the circulatory system and bypass the liver’s filtration mechanism, which digested medicines would normally be subject to. DehydraTECH’s lymph vessel delivery approach also has several advantages over digested medicines by decreasing concerns about taste, improving neurological delivery across the blood brain barrier, reducing the amount of drugs needed for usefulness, and decreasing the risk of side effects. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” CEO Chris Bunka said of the company’s brand partnerships earlier this summer (https://ibn.fm/PfLMa). “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.” For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX